Trial Profile
A randomized phase 3 trial of Alimta (pemetrexed) and carboplatin versus etoposide and carboplatin in extensive-stage small cell lung cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms GALES
- Sponsors Eli Lilly and Company
- 19 Dec 2011 Biomarker analysis results published in Annals of Oncology.
- 27 Aug 2009 Interim analysis results have been reported in the Journal of Clinical Oncology.
- 12 Nov 2008 Status changed from discontinued to completed, as reported by clinicaltrials.gov.